Alexander M. Lesokhin
Memorial Sloan Kettering Cancer Center
282 Papers
526 Citations
Alexander M. Lesokhin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 33, co-authored 138 publications. Previous affiliations of Alexander M. Lesokhin include Cornell University & Bristol-Myers Squibb.
Chat about Author
Papers
P-467 Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse national health and nutrition examination survey (NHANES) case-control study
Janine Joseph,Li Tang,J. Hillengass,Ola Landgren,Saad Usmani,Alexander M. Lesokhin,Kirsten Moysich,Urvi A Shah +7 more
Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.
Francesco Maura,Even H Rustad,Venkata Yellapantula,Marta Łuksza,David Hoyos,Kylee H Maclachlan,Benjamin Diamond,Benjamin Greenbaum,Gareth J. Morgan,Alexander M. Lesokhin,Elli Papaemmanuil,Ola Landgren +11 more
TL;DR: A striking pattern emerged reflecting the differential temporal activity of AID and APOBEC during MM pathogenesis, and the chronological order of acquisition of SNVs in driver genes was reconstructed in 788 patients with MM.
Recycling is "bad to the bone" in patients with myeloma.
Kevin C Miller,Alexander M. Lesokhin +1 more
P-007 Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/ refractory multiple myeloma
Bruno Costa,Jessica R. Flynn,Karthik Nath,Noriko Nishimura,Sean M. Devlin,Tasmin Farzana,David Chung,Heather Landau,Oscar B Lahoud,Michael Scordo,Gunjan L. Shah,Hani Hassoun,Kylee H Maclachlan,Malin Hultcrantz,Neha Korde,Alexander M. Lesokhin,Urvi A Shah,C. Tan,Sergio Giralt,Saad Usmani,Sham Mailankody +20 more
Stem Cell Utilization in the Era of Novel Therapies for Multiple Myeloma
Noriko Nishimura,D. M. Nemirovsky,Sean M. Devlin,Parastoo B. Dahi,Heather Landau,Oscar B Lahoud,Michael Scordo,Gunjan L. Shah,Sham Mailankody,Hani Hassoun,Kylee H Maclachlan,Malin Hultcrantz,Neha Korde,Alexander M. Lesokhin,Urvi A Shah,C. Tan,Gaurav Gupta,E. Maryamchik,R. Pattarkine,Grace Linder,Saad Usmani,Sergio A. Giralt,David Chung +22 more
TL;DR: Stem cell utilization for second, non-tandem (salvage) ASCT and/or stem cell boost over time and progression-free survival (PFS) and overall survival (OS) from the time of salvage ASCT using the Cox proportional hazard model are determined.